Abstract
Benznidazole (BZ) is the frontline drug used against Trypanosoma cruzi, the causative agent of Chagas disease, which affects 10 million people in Latin America. However, treatment failures are frequently reported, attributed mainly to the diversity of drug susceptibility within natural parasite populations and/or the development of drug resistance. Evidence of our group indicate that an A…